Published in Cell on March 06, 2009
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
MicroRNAs in stress signaling and human disease. Cell (2012) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
MicroRNA functions in stress responses. Mol Cell (2010) 4.46
Identification of aneuploidy-selective antiproliferation compounds. Cell (2011) 4.45
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev (2011) 3.05
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77
Nrf2: friend or foe for chemoprevention? Carcinogenesis (2009) 2.72
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal (2010) 2.64
The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature (2015) 2.63
Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity. Cancer Cell (2009) 2.58
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med (2015) 2.53
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis (2010) 2.46
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature (2015) 2.45
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell (2013) 2.34
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Metabolic flux and the regulation of mammalian cell growth. Cell Metab (2011) 2.27
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell (2012) 2.08
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell (2014) 2.06
High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A (2011) 2.03
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell (2016) 2.03
Generation of iPSCs from cultured human malignant cells. Blood (2010) 1.99
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer (2010) 1.97
Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov (2012) 1.96
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
Malignant pirates of the immune system. Nat Immunol (2011) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival. Cancer Res (2011) 1.83
Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer (2013) 1.80
Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Semin Cell Dev Biol (2009) 1.78
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell (2009) 1.72
Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev (2011) 1.71
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer Cell (2015) 1.65
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood (2012) 1.64
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets (2010) 1.62
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett (2011) 1.55
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med (2010) 1.55
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell (2010) 1.52
Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med (2010) 1.52
Differential network entropy reveals cancer system hallmarks. Sci Rep (2012) 1.52
Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer (2010) 1.51
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med (2014) 1.49
Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res (2010) 1.47
Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab (2011) 1.47
Altered metabolism in cancer. BMC Biol (2010) 1.46
Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. J Pathol (2016) 1.45
Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle (2009) 1.44
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell (2016) 1.43
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev (2010) 1.42
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res (2012) 1.41
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res (2015) 1.40
Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A (2012) 1.40
Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene (2010) 1.40
Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell (2014) 1.39
Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett (2010) 1.39
Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation. Oncogene (2010) 1.37
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol (2012) 1.36
Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer (2013) 1.36
The endoplasmic reticulum stress response in aging and age-related diseases. Front Physiol (2012) 1.35
A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell (2014) 1.35
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest (2011) 1.35
Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br J Cancer (2012) 1.35
The hallmarks of cancer. Cell (2000) 113.05
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
On the origin of cancer cells. Science (1956) 49.55
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
The DNA damage response: ten years after. Mol Cell (2007) 11.80
5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer (2003) 11.78
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
An oncogene-induced DNA damage model for cancer development. Science (2008) 11.60
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 11.20
Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell (2008) 11.18
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature (2006) 11.18
Cell cycle control and cancer. Science (1994) 10.90
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature (2009) 10.31
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature (2007) 9.25
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell (2007) 9.20
Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer (2006) 9.15
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell (2007) 8.84
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science (2007) 7.69
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res (1991) 6.99
Dosage sensitivity and the evolution of gene families in yeast. Nature (2003) 6.77
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Oncogene addiction. Cancer Res (2008) 5.66
Modelling the molecular circuitry of cancer. Nat Rev Cancer (2002) 5.43
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science (2008) 5.36
Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol (2001) 5.10
Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer (2006) 4.99
Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev (2007) 4.96
Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (1993) 4.76
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Connecting chromosomes, crisis, and cancer. Science (2002) 4.69
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem (1999) 4.38
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell (2005) 3.69
Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet (2000) 3.67
Aneuploidy: cells losing their balance. Genetics (2008) 3.48
Telomerase and cancer therapeutics. Nat Rev Cancer (2008) 3.46
Role of autophagy in cancer: management of metabolic stress. Autophagy (2007) 3.40
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Non-oncogene addiction and the stress phenotype of cancer cells. Cell (2007) 3.19
Mitochondria in cancer cells: what is so special about them? Trends Cell Biol (2008) 2.97
Genome-wide genetic analysis of polyploidy in yeast. Nature (2006) 2.85
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov (2007) 2.40
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res (2007) 2.27
Microenvironmental regulation of cancer development. Curr Opin Genet Dev (2008) 2.25
The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A (1994) 2.15
A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev (1991) 2.14
ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science (2007) 20.11
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science (2003) 18.29
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
Dicer is essential for mouse development. Nat Genet (2003) 15.87
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
The DNA damage response: ten years after. Mol Cell (2007) 11.80
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96
A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A (2008) 10.07
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell (2009) 7.88
Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat Methods (2007) 7.56
MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature (2003) 6.81
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science (2007) 6.77
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell (2007) 6.68
A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 6.36
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
Cancer proliferation gene discovery through functional genomics. Science (2008) 5.41
Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell (2009) 5.41
A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A (2005) 5.29
53BP1, a mediator of the DNA damage checkpoint. Science (2002) 5.00
RNA interference screen for human genes associated with West Nile virus infection. Nature (2008) 4.93
The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science (2009) 4.85
BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. Nature (2003) 4.79
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A (2007) 4.75
Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev (2004) 4.68
Regulation of ATR substrate selection by Rad17-dependent loading of Rad9 complexes onto chromatin. Genes Dev (2002) 4.58
Profiling essential genes in human mammary cells by multiplex RNAi screening. Science (2008) 4.51
A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev (2009) 4.23
Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature (2007) 4.14
Global protein stability profiling in mammalian cells. Science (2008) 3.91
Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc Natl Acad Sci U S A (2003) 3.88
Checking on the fork: the DNA-replication stress-response pathway. Trends Cell Biol (2002) 3.66
The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol (2007) 3.63
Mrc1 is a replication fork component whose phosphorylation in response to DNA replication stress activates Rad53. Genes Dev (2003) 3.59
A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell (2010) 3.51
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41
The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A (2011) 3.40
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci U S A (2009) 3.37
SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev (2003) 3.35
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci U S A (2010) 3.31
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog (2011) 3.26
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev (2009) 3.23
FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol (2008) 3.22
Non-oncogene addiction and the stress phenotype of cancer cells. Cell (2007) 3.19
Global identification of modular cullin-RING ligase substrates. Cell (2011) 3.13
Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A (2004) 3.12
A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell (2006) 3.10
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog (2011) 2.99
Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell (2004) 2.94
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature (2008) 2.86
The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell (2002) 2.85
SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature (2008) 2.84
Multiple tumor suppressor pathways negatively regulate telomerase. Cell (2003) 2.82
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Lessons from Nature: microRNA-based shRNA libraries. Nat Methods (2006) 2.80
Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci U S A (2004) 2.66
MAGIC, an in vivo genetic method for the rapid construction of recombinant DNA molecules. Nat Genet (2005) 2.63
Design of 240,000 orthogonal 25mer DNA barcode probes. Proc Natl Acad Sci U S A (2009) 2.61
The mitotic spindle is required for loading of the DASH complex onto the kinetochore. Genes Dev (2002) 2.60
Identification of SCF ubiquitin ligase substrates by global protein stability profiling. Science (2008) 2.53
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol (2012) 2.51
The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in replication fork restart. Genes Dev (2009) 2.44
Towards genetic genome projects: genomic library screening and gene-targeting vector construction in a single step. Nat Genet (2001) 2.21
An open letter to Elias Zerhouni. Science (2005) 2.19
FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Mol Cell (2008) 2.14
Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability. J Biol Chem (2003) 2.03
A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol (2007) 2.00
A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev (2010) 1.98
CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell (2008) 1.94
Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol (2011) 1.90
BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A (2005) 1.90
Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell (2009) 1.85
Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep (2012) 1.84
Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A (2007) 1.83
Tipin and Timeless form a mutually protective complex required for genotoxic stress resistance and checkpoint function. Proc Natl Acad Sci U S A (2006) 1.81
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A (2007) 1.79
A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science (2011) 1.79
Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress. Mol Cell (2012) 1.79
Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol (2012) 1.77
Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A (2010) 1.76
Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J Biol Chem (2004) 1.74
The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev (2010) 1.74
Wnt signaling regulates mitochondrial physiology and insulin sensitivity. Genes Dev (2010) 1.71
Genetic and physical interactions between DPB11 and DDC1 in the yeast DNA damage response pathway. Genetics (2002) 1.66
Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress. Mol Cell (2006) 1.65
An open letter to cancer researchers. Science (2005) 1.65
Genomic instability and endoreduplication triggered by RAD17 deletion. Genes Dev (2003) 1.64
SLIC: a method for sequence- and ligation-independent cloning. Methods Mol Biol (2012) 1.64
Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A (2004) 1.62
The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A (2007) 1.61
Structure of the FANCI-FANCD2 complex: insights into the Fanconi anemia DNA repair pathway. Science (2011) 1.58